Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed 45 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer

Timeline

Start: 2003-12
Primary completion: 2010-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cilengitide	Peptide	—	Intravenous

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Summary

Timeline

Drugs

Indications